- Home
- NTIP vs FGEN Comparison
NTIP vs FGEN Comparison
Compare NTIP & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- FGEN
- Stock Information
- Founded
- NTIP 1990
- FGEN 1993
- Country
- NTIP United States
- FGEN United States
- Employees
- NTIP N/A
- FGEN N/A
- Industry
- NTIP Multi-Sector Companies
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- FGEN Health Care
- Exchange
- NTIP Nasdaq
- FGEN Nasdaq
- Market Cap
- NTIP 28.6M
- FGEN 33.5M
- IPO Year
- NTIP 1998
- FGEN 2014
- Fundamental
- Price
- NTIP $1.34
- FGEN $7.26
- Analyst Decision
- NTIP
- FGEN Strong Buy
- Analyst Count
- NTIP 0
- FGEN 1
- Target Price
- NTIP N/A
- FGEN $250.00
- AVG Volume (30 Days)
- NTIP 25.7K
- FGEN 74.7K
- Earning Date
- NTIP 08-11-2025
- FGEN 08-05-2025
- Dividend Yield
- NTIP 7.62%
- FGEN N/A
- EPS Growth
- NTIP N/A
- FGEN N/A
- EPS
- NTIP N/A
- FGEN N/A
- Revenue
- NTIP $250,000.00
- FGEN $6,996,000.00
- Revenue This Year
- NTIP N/A
- FGEN N/A
- Revenue Next Year
- NTIP N/A
- FGEN N/A
- P/E Ratio
- NTIP N/A
- FGEN N/A
- Revenue Growth
- NTIP N/A
- FGEN N/A
- 52 Week Low
- NTIP $1.16
- FGEN $4.50
- 52 Week High
- NTIP $1.78
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- NTIP 62.14
- FGEN 60.54
- Support Level
- NTIP $1.20
- FGEN $5.37
- Resistance Level
- NTIP $1.30
- FGEN $5.73
- Average True Range (ATR)
- NTIP 0.06
- FGEN 0.49
- MACD
- NTIP 0.01
- FGEN 0.27
- Stochastic Oscillator
- NTIP 69.23
- FGEN 83.80
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.